MARKET

SPRO

SPRO

Spero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.50
+0.54
+4.52%
After Hours: 12.40 -0.1 -0.80% 17:39 05/22 EDT
OPEN
12.17
PREV CLOSE
11.96
HIGH
12.76
LOW
12.05
VOLUME
221.91K
TURNOVER
--
52 WEEK HIGH
14.38
52 WEEK LOW
5.25
MARKET CAP
257.44M
P/E (TTM)
-2.9806
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SPRO stock price target is 22.33 with a high estimate of 31.00 and a low estimate of 7.00.

EPS

SPRO News

More
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO
NEW YORK, NY / ACCESSWIRE / May 25, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ:SPRO). Such investors ...
ACCESSWIRE · 6h ago
Spero Therapeutics (SPRO) Presents At Bank of America Healthcare Virtual Conference 2020 - Slideshow
Seeking Alpha - Article · 05/13 15:56
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO
Pomerantz LLP is investigating claims on behalf of investors of Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation
GlobeNewswire · 05/13 15:12
SPRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spero Therapeutics, Inc. ("Spero" or "the Company") ...
ACCESSWIRE · 05/12 20:55
Spero Therapeutics, Inc. (SPRO) Shares March Higher, Can It Continue?
Zacks · 05/12 14:50
Spero Therapeutics, Inc. (SPRO) CEO Dr. Ankit Mahadevia on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/12 04:24
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Raises Price Target to $28
HC Wainwright & Co. reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $25 to $28.
Benzinga · 05/11 11:44
H.C. Wainwright Sticks to Their Buy Rating for Spero Therapeutics Inc
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) Inc on Monday, setting a price target of $28, which is approximately 137.69% above the present share price of $11.78.
Investing.com · 05/11 10:53

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.
More

Webull offers kinds of Spero Therapeutics Inc stock information, including NASDAQ:SPRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRO stock news, and many more online research tools to help you make informed decisions.